Aligos Therapeutics (ALGS) Return on Invested Capital (2021 - 2025)
Historic Return on Invested Capital for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 1.0%.
- Aligos Therapeutics' Return on Invested Capital rose 6200.0% to 1.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.0%, marking a year-over-year increase of 6200.0%. This contributed to the annual value of 2.83% for FY2024, which is 19300.0% down from last year.
- Aligos Therapeutics' Return on Invested Capital amounted to 1.0% in Q3 2025, which was up 6200.0% from 0.72% recorded in Q2 2025.
- Aligos Therapeutics' Return on Invested Capital's 5-year high stood at 0.64% during Q4 2021, with a 5-year trough of 8.46% in Q4 2024.
- Its 5-year average for Return on Invested Capital is 1.57%, with a median of 1.06% in 2023.
- In the last 5 years, Aligos Therapeutics' Return on Invested Capital crashed by -72500bps in 2024 and then soared by 7500bps in 2025.
- Aligos Therapeutics' Return on Invested Capital (Quarter) stood at 0.64% in 2021, then tumbled by -35bps to 0.86% in 2022, then plummeted by -40bps to 1.21% in 2023, then plummeted by -599bps to 8.46% in 2024, then surged by 88bps to 1.0% in 2025.
- Its Return on Invested Capital was 1.0% in Q3 2025, compared to 0.72% in Q2 2025 and 1.99% in Q1 2025.